Welcome to our Resource Archive
Our NETest has been the subject of over 60 Peer-reviewed research projects with a wide variety of objectives: clinical utility, monitoring therapy, as a surgical biomarker. We also have research about our mRNA-based science platform, diagnostics in our pipeline such as PROSTest and our saliva-based COVID-19 diagnostics. If you click one of the buttons below, you can filter our research by area of interest.
If you would like to discuss a research topic involving our NETest, PROStest or another molecular diagnostic, please contact Dr. Mark Kidd, our Scientific and Laboratory Director.
November 10 is Neuroendocrine Cancer Awareness Day. As a company founded to bring a NET diagnostic to market, awareness of Neuroendocrine Cancer has been part of our mission from Day One. To this end, we join the NET community in creating awareness around this rare but rising disease.
In 2010, the World NET Community Steering Committee proclaimed November 10 as Worldwide Neuroendocrine Cancer Awareness Day. Since then, the recognition has expanded beyond a single day, and November is now observed by many in the NET community as Neuroendocrine...
This past Saturday, a team of Wren employees gathered at the Yale Bowl for the 13th Closer to Free Ride in support of Smilow Cancer Hospital. The ride ("it's not a race, it's a ride" is the oft-heard phrase among Closer to Free veteran riders) is the principal...
The Wren Laboratories NETest and its recent expansion into the Chinese Market was the subject of a feature article by Forest Ray in GenomeWeb.com. The article characterized our decision to focus on mRNA as the basis for our diagnostic platform and also discusses a little bit about diagnostics in our pipeline, specifically our PROSTest.
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.
Development and validation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection
Secretory tumor markers traditionally measured in patients with neuroendocrine tumors (NET) are lacking sensitivity and specificity, and consequently they are of limited clinical utility.
Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for177Lu-PSMA therapy in advanced prostate cancer
With the prostate-specific antigen (PSA) test now considered a less-than-reliable screen for prostate cancer, a worldwide search is under way to find an inexpensive, minimally invasive, and more effective tool to replace what was once considered the gold standard biomarker.
Barbadian doctors said Friday they are on the verge of groundbreaking research on a test for the illness which they believe could significantly reduce the prostate cancer epidemic and remove the often-daunting rectal examination to find the disease.
Yale University, Wren Laboratories and the Barbados Cancer Society have teamed to screen over 500 Barbadian men for molecular signatures indicating the presence of prostate cancer.
The Wren Laboratories NETest was selected as the diagnostic tool in study of a precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients.
The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors (NETs). It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, providing an accurate molecular profile of the neoplasm.
ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET)
Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection
Surgical resection is the only effective curative strategy for small intestinal neuroendocrine neoplasms (SINENs). Nevertheless, the evaluation of residual disease and prediction of disease recurrence/progression remains a problematic issue.
The NETest PPQ–Peptide Receptor Radionuclide Therapy Predictor Quotient–exhibits over 97% accuracy in predicting positive response to PRRT for metastatic/inoperable NETs in real time.
Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management
Relative to prostate-specific antigen (PSA), our mRNA-based diagnostic emerges as a more dependable biomarker, with an accuracy rate exceeding 90%, and readily repeatable while providing real-time information.
The NETest, a multigene blood biomarker, is more accurate at predicting recurrence in NET resection surgery patients, providing greater efficiency for oncologists in managing neuroendocrine cancer treatment.
Recent research published in the Journal of Nuclear Medicine (April '23) has validated the NETest and PPQ as a predictor of PRRT effectiveness in treating some NETs.
The Wren PROSTest is a 27-gene blood biopsy biomarker delivering greater than 90% accuracy in diagnosing and monitoring prostate cancer.
The NETest exhibited a 93% sensitivity and 89% specificity in identifying and differentiating lung malignancies including NSCLC from NETs.
This study demonstrates sensitivity and specificity benefits of a blood-based multianalyte NET gene transcript measurement to detect GI tract cancer.
PPQ or PRredicTor, a subset of NETest analytes, deliver 94% accuracy in predicting response to Peptide Receptor Radionuclide Therapy
Neuroendocrine Neoplasia Diagnosis: mRNA biomarker NETest exhibits 3-5 times greater accuracy than Chromogranin A
NETest, a multigenomic mRNA biomarker exhibiting ~99% accuracy in NEN disease identification; is far more accurate than CgA (19–33%) and should be considered the biomarker standard of care.